FDA Approves Bristol Myers Squibb’s Opdivo and Yervoy Combination Immunotherapy

The Food and Drug Administration (FDA) has approved Bristol Myers Squibb’s (BMS) Opdivo (nivolumab) in combination with Yervoy (ipilimumab) for an undisclosed indication. This regulatory decision allows for the combined use of these two immunotherapy drugs. Opdivo, also known as nivolumab, and Yervoy, known as ipilimumab, are both manufactured by Bristol Myers Squibb. The FDA’s approval now permits physicians to prescribe the combination of these two drugs for the approved use. The specific details of the indication for which this combination therapy received approval were not disclosed.

Newsflash | Powered by GeneOnline AI
Date: April 14, 2025

Author

Mark Chiang